DEXLEVO
DEXLEVO, an aesthetic medical device company, attended the international conference on cosmetic formation opening in Paris, IMCAS World Congress 2022 on 2022.06.03~06.05, and introduced the excellence and effectiveness of ‘GOURI’.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220630005382/en/
IMCAS World Congress is one of the world’s top 3 cosmetic conferences, is an event where over 20,000 visitors from more than 195 countries, including dermatologists, participate every year to share the latest knowledge of the industry.
DEXLEVO held its own symposium at the IMCAS World Congress where they participated for the first time as an Emerald sponsor and demonstrated GOURI treatment techniques. As much as GOURI’s technology and product differentiation was verified by being awarded the Best injectable Collagen Inducer at the AMWC held in Monaco last April, many distributors and doctors attended and gathered attention.
Through the symposium, it was introduced, “The current trend in the cosmetic market is anti-aging, and consumers want natural skin improvement. GOURI satisfies all of the market and consumers’ needs with their natural collagen regenerative effect. Not only that, it is safe compared to competitive products, and the surgical procedure is easy, so the satisfaction level in doctors and patients are both high.”
A DEXLEVO employee said, “We were able to confirm that the awareness of GOURI has increased through this conference. Given that the conference was held at the same level as before Covid-19, I have gained confidence to respond to the demand in the beauty market that will increase after the endemic.
Starting with the launch of GOURI last year, DEXLEVO has been actively discussing contracts with large companies in more than 40 countries including Europe, and in May, it formed a strategic partnership with GS Global to explore global markets. It has signed a distribution and sales contract worth $10 million (about KRW 12.7billion) in Turkey, and plans to expand its market to the EU, MENA, East Asia, and China, including Germany.
After the acquisition of Hugel, GS took its first step into the bio market with DEXLEVO’s ‘GOURI’, which is interpreted as the judgment that GOURI’s technological competitiveness and differentiation can create synergy with its business portfolio. Also, GOURI can be supplemented with botonium toxin, and the expansion of the esthetic distribution network through GOURI is expected to have a synergistic effect when expanding its business portfolio in the future. A GS official said, “The collaboration with DEXLEVO through GOURI is to secure future growth engines for GS Group.”
Meanwhile, it is waiting for approval from the Ministry of Food & Drug Safety (MFDS) after clinical completion in Korea, and is aiming to release products next year.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220630005382/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Compass Pathways Announces FDA Acceptance of IND Application for PTSD and Hosts Webinar on PTSD and TRD7.1.2026 12:30:00 CET | Press release
FDA Accepts Investigational New Drug (IND) Application for COMP360 for the treatment of post-traumatic stress disorder (PTSD), enabling initiation of late-stage trialCompass continues to advance commercial preparations to be launch-ready by the end of the year for COMP360 for treatment-resistant depression (TRD)Management will host webinar with KOL and industry leaders to discuss PTSD clinical trial and commercial preparations for TRD from 10:00-11:30 am ET on January 7th Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for COMP360, enabling the initiation of a late-stage clinical trial in patients with PTSD. Compass management, along with KOL and industry leaders, will host a webinar today to discuss the company’s clinical trial plans for PTSD, as well as commercial preparations f
Stallergenes Greer Expands Venom Immunotherapy Production Capacity With Acquisition of Entomon s.r.l.7.1.2026 11:07:00 CET | Press release
Stallergenes Greer, a global leader in allergy therapeutics, today announced that it has entered into an agreement to acquire Entomon s.r.l., an Italian company specialising in the production of certified stinging-insect venom extracts, notably of the Hymenoptera order, used for the manufacture of diagnostic preparations and Venom Immunotherapy (VIT). The transaction is expected to close by the end of January. Entomon, currently recognised as the only company in Europe capable of extracting pure venom from Hymenoptera insects, produces pharmaceutical-grade insect venom using proprietary techniques (Entomon Capillary Extracted Venom®) for medical use. Through this acquisition, Stallergenes Greer bolsters its venom manufacturing capabilities and supply of raw materials for life-saving VIT treatments, whilst safeguarding patient care continuity. Hymenoptera venom allergy is the most common trigger of severe anaphylaxis in adults1. According to the EAACI guidelines on venom immunotherapy,
ARIS Announces New CEO to Lead Agentic AI-led Strategy7.1.2026 10:00:00 CET | Press release
CEO Appointment ARIS, a global leader in process intelligence and transformation software, today announced the appointment of Guillaume Bacuvier as Chief Executive Officer. Guillaume will lead ARIS through its next phase of growth as a fully standalone company, accelerating its evolution from a market leader in Process Intelligence into a foundational platform for enterprises deploying and governing Agentic AI. Guillaume brings deep international leadership experience across technology, data, and software-enabled businesses, with a proven track record of scaling global platforms and leading complex organisations. After starting as a strategic consultant at Booz Allen Hamilton, Guillaume spent over a decade at Google, rising to Vice President in EMEA where he built and scaled some of Google’s largest data-driven businesses in Europe and held P&L responsibility across multiple countries. In the last decade, Guillaume has served as CEO of multi-continent, data-centric companies including
I Squared Capital Acquires Ramudden Global, a Leader in Traffic Management and Infrastructure Safety7.1.2026 09:00:00 CET | Press release
Acquisition will accelerate Ramudden’s ambitious growth plan across North America and Europe supported by strong infrastructure spending tailwinds I Squared Capital, a leading global infrastructure investment manager, today announced that, through its flagship fund, it has agreed to acquire Ramudden Global, from funds advised by Triton Partners (“Triton”), a leading European mid-market sector-specialist investor. Ramudden Global is a leading international provider of traffic management and infrastructure safety services supporting the maintenance and upgrade of essential transport and utility networks. The company operates more than 190 depots across 13 countries in Europe and North America delivering mission-critical services that help to ensure safety, regulatory compliance and continuity of service across road, utility and broader infrastructure works. This investment underscores I Squared Capital’s commitment to investing in essential, regulated, infrastructure businesses that unde
RoslinCT and BOOST Pharma Announce Strategic Manufacturing Agreement to Advance Cell Therapy for Infants with Osteogenesis Imperfecta7.1.2026 09:00:00 CET | Press release
RoslinCT, a global contract development and manufacturing organization (CDMO) specializing in advanced cell therapies, and BOOST Pharma, a clinical-stage biotechnology company developing first-in-class cell therapies for rare paediatric skeletal diseases, today announced a strategic manufacturing partnership to support the development of BOOST Pharma’s cell therapy, BT-101, for the treatment of infants with Osteogenesis Imperfecta (OI), also known as brittle bone disease. Under the service agreement, BOOST Pharma has transferred its manufacturing process to RoslinCT’s state-of-the-art facilities in Edinburgh, Scotland. The partnership will progress toward GMP manufacturing of starting materials and clinical drug product, supporting Phase III clinical development of BT-101. The therapy is an allogeneic mesenchymal stem cell (MSC) product designed to address the underlying cause of OI at the earliest stages of life. BOOST Pharma was founded on pioneering science originating from Karolins
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom